A5086583959- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Liver Disease Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Organ Donation and Transplantation
- Renal and Vascular Pathologies
- Transplantation: Methods and Outcomes
- Hepatitis C virus research
- Liver Diseases and Immunity
- Gallbladder and Bile Duct Disorders
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Clinical Nutrition and Gastroenterology
- Nutrition and Health in Aging
- Hepatitis B Virus Studies
- Neurological Complications and Syndromes
- HIV/AIDS drug development and treatment
- Genetic and Kidney Cyst Diseases
- Vascular anomalies and interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- Congenital Anomalies and Fetal Surgery
- Pancreatitis Pathology and Treatment
- Diet and metabolism studies
- Bone and Joint Diseases
University of Maryland, Baltimore
2022-2025
Virginia Commonwealth University
2015-2025
University of Maryland Medical Center
2022-2024
University Health System
2019-2022
Virginia Commonwealth University Medical Center
2022
Children's Hospital of Richmond at VCU
2019-2020
Medical University of Vienna
2020
Ospedale regionale di Lugano
2020
University of Illinois Chicago
2011-2014
University of Chicago Medical Center
2014
Ischemic cold storage (ICS) of livers for transplant is associated with serious posttransplant complications and underuse liver allografts.To determine whether portable normothermic machine perfusion preservation obtained from deceased donors using the Organ Care System (OCS) Liver ameliorates early allograft dysfunction (EAD) ischemic biliary (IBCs).This multicenter randomized clinical trial (International Randomized Trial to Evaluate Effectiveness Portable Preserving Assessing Donor Livers...
In Brief Background Nonalcoholic steatohepatitis (NASH), a clinically aggressive variant of nonalcoholic fatty liver disease (NAFLD), is becoming an increasingly common indication for transplantation (LT); however, relatively little known regarding its clinical course post-LT. The aim the current study to describe recurrence and after LT. Methods All surviving patients transplanted NASH at authors' institution had transient elastography (TE) evaluate hepatic steatosis fibrosis. charts...
Coronary artery disease (CAD) is an important contributor to morbidity and mortality in patients undergoing liver transplantation (LT). However, the current literature limited by sampling bias nondefinitive assessment of CAD. The study examines prevalence CAD via per protocol coronary angiography its relationship etiology evaluation (LTE). Data on 228 were prospectively collected who had as part LTE between 2011 2014. was done all age ≥50 years or with risk factors. defined any stenosis,...
We conducted an adaptive design single-center pilot trial between October 2017 and November 2018 to determine the safety efficacy of ultra-short-term perioperative pangenotypic direct acting antiviral (DAA) prophylaxis for deceased hepatitis C virus (HCV)-nucleic acid test (NAT) positive donors HCV negative kidney recipients (D+/R−). In Group 1, 10 patients received one dose SOF/VEL (sofusbuvir/velpatasvir) pretransplant on posttransplant Day 1. 2A (N = 15) posttrial validation (Group 2B; N...
Cardiovascular disease (CVD) is a major contributor to longterm mortality after liver transplantation (LT) necessitating aggressive modification of CVD risk. However, it unclear how coronary artery (CAD) and the development dyslipidemia following LT impacts clinical outcomes management these factors may impact survival. Patients undergoing at Virginia Commonwealth University from January 2007 2017 were included (n = 495). CAD risk in all potential recipients (LTRs) over age 50 years...
There is no literature on the use of belatacept for sensitized patients or regrafts in kidney transplantation. We present our initial experience high immunologic risk transplant recipients who were converted from tacrolimus to presumed acute calcineurin inhibitor (CNI) toxicity and/or interstitial fibrosis/tubular atrophy. Six (mean age = 40 years) switched at a median 4 months posttransplant. Renal function improved significantly peak mean estimated glomerular filtration rate (eGFR) 23.8 ±...
Coronary artery disease (CAD) assessment is a vital part of liver transplantation (LT) evaluation, as it allows for identification and medical optimization prior to transplantation. Although aspirin statins are standard care CAD, they not universally used in cirrhosis due concerns about adverse events. Per protocol, coronary angiography was performed the LT evaluation all patients over age 50 years or with CAD risk factors, even if were younger than 50. Optimal management defined use both...
Molecular diagnosis of rejection is emerging in kidney, heart, and lung transplant biopsies could offer insights for liver biopsies. We measured gene expression by microarrays 235 from 10 centers. Unsupervised archetypal analysis based on previously annotated rejection-related transcripts identified 4 groups: normal "R1normal " (N = 129), T cell-mediated (TCMR) "R2TCMR 37), early injury "R3injury 61), fibrosis "R4late 8). Groups differed median time posttransplant, example, R3injury 99 days...
Background. Initial analysis of liver transplant biopsies in the INTERLIVER study (ClinicalTrials.gov; unique identifier NCT03193151) using rejection-associated transcripts failed to find an antibody-mediated rejection state (ie, rich natural killer [NK] cells and with interferon-gamma effects). We recently developed optimization strategy lung transplants that isolated NK cell–enriched rejection-like (NKRL) was molecularly distinct from T cell–mediated (TCMR). Here we apply same a biopsy...
Piggyback syndrome is a rare complication of orthotopic liver transplant performed via the piggyback technique. Where conventional involves anastomosis both donor and recipient inferior vena cava, instead between cava hepatic veins. vein outflow obstruction as result anastomotic stenosis after transplant. We present case successfully treated with percutaneous stenting balloon angioplasty discuss etiology, diagnosis, treatment this syndrome.
Cardiovascular complications are major contributors to mortality at liver transplantation (LT). However, the impact of coronary artery disease (CAD) on these is not well-understood as literature limited by non-invasive assessment CAD, which suboptimal in patients with cirrhosis. Thus, current study evaluated cardiovascular events LT stratified according presence and severity CAD quantified angiography.
Cardiovascular disease (CVD) is an important cause of morbidity and mortality after liver transplantation (LT). Although LT associated with dyslipidemia, particularly atherogenic lipoprotein subparticles, the impact these subparticles on CVD-related events unknown. Therefore, aim current study was to evaluate small dense (sdLDL-C) low-density (LDL) cholesterol (LDL-C) CVD events. Prospectively enrolled patients (N = 130) had detailed lipid profile consisting traditional parameters sdLDL-C...
To report the prevalence and outcome of cholangiocarcinoma arising in primary sclerosing cholangitis for a British tertiary referral centre.All patients diagnosed with concurrent were identified from prospectively maintained departmental database, mode presentation, management determined.Of 370 cholangitis, 48 (13%) within median time 0.51 months (range: 0-73.12) presentation to unit. Mode included: inoperable tumours (n = 14); incidental findings transplant hepatectomy specimens 13);...
Nonalcoholic fatty liver disease is associated with cardiovascular (CVD) in the general population. Despite a high prevalence of de novo hepatic steatosis after transplantation (LT), there are no data exploring association between LT and atherogenic risk. The aim study was to explore impact on serum markers recipients (LTRs). Biomarkers CVD risk were compared 89 LTRs known history dyslipidemia, ischemic heart disease, or graft cirrhosis. To avoid potential confounders, oral hypoglycemic...